Geron Corporation - Common Stock (GERN)

Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $

Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS. Dur

RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.

Geron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndromes, or MDS. Chief Executive Officer Harout Semerjian said first-half net

Geron (GERN) Q1 2026 Earnings Call Transcript

Geron (GERN) Q4 2025 Earnings Call Transcript

Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates.

Geron's Q3 2025 results show mixed performance, with RYTELO revenue up 67% year-over-year but missing analyst sales estimates, causing a negative market reaction.

GERN earnings call for the period ending December 31, 2024.